Efficacy of a Novel BCL-xL Degrader, DT2216, in Preclinical Models of JAK2-mutated Post-MPN AML.
Wang Z. et al, (2025), Blood
Molecular profiling in MPN: who should have it and why?
Chee A. and Mead AJ., (2024), Hematology Am Soc Hematol Educ Program, 2024, 524 - 534
A proinflammatory stem cell niche drives myelofibrosis through a targetable galectin-1 axis.
Li R. et al, (2024), Sci Transl Med, 16
Clinical utility of investigations in triple-negative thrombocytosis: A real-world, multicentre evaluation of UK practice.
Godfrey AL. et al, (2024), Br J Haematol
Alternative platelet differentiation pathways initiated by nonhierarchically related hematopoietic stem cells.
Carrelha J. et al, (2024), Nat Immunol, 25, 1007 - 1019
Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis.
Gerds AT. et al, (2024), Blood Adv
Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis.
Oh ST. et al, (2024), EJHaem, 5, 105 - 116
Efficacy of a Novel BCL-XL Degrader, DT2216, in Preclinical Models of Post-Myeloproliferative Neoplasm Secondary AML
Wang Z. et al, (2024), BLOOD, 144, 2749 - 2751
Implementing human bone marrow organoids to interrogate microenvironmental influences on the efficacy of blood cancer immunotherapies
Wong ZC. et al, (2024), CANCER RESEARCH, 84
Interim Analysis of Promise, a Clinical Study Combining the BET Inhibitor OPN-2853 with Ruxolitinib in Patients with Advanced Myelofibrosis Experiencing an Inadequate Response to Ruxolitinib
Mead AJ. et al, (2024), BLOOD, 144, 3186 - 3187
Real World Efficacy and Safety of Momelotinib for Myelofibrosis: Evaluation of a UK-Wide Study Confirms 40% Anaemia Response Rate in a Non-Clinical Trial Cohort
Rampotas A. et al, (2024), BLOOD, 144, 1804 - 1806
Single-Cell Multiomic Profiling of TP53 Mutated Myelodysplastic Neoplasms- All Clones Are Not Equal
Chowdhury O. et al, (2024), BLOOD, 144, 3615 - 3616
Spatial Transcriptomics Identifies Aberrant Communication between Dendritic Cells and Leukemia Stem Cells As a Therapeutically Targetable Axis in Juvenile Myelomonocytic Leukemia
Louka E. et al, (2024), BLOOD, 144, 822 - 823
Backtracking to the future: unraveling the origins of childhood leukemia.
de Smith AJ. et al, (2023), Leukemia
Chromothripsis orchestrates leukemic transformation in blast phase MPN through targetable amplification of DYRK1A.
Brierley CK. et al, (2023), bioRxiv
Perivascular niche cells sense thrombocytopenia and activate hematopoietic stem cells in an IL-1 dependent manner
Luis TC. et al, (2023), Nature Communications, 14
The management of myelofibrosis: A British Society for Haematology Guideline.
McLornan DP. et al, (2023), Br J Haematol
Tamoxifen for the treatment of myeloproliferative neoplasms: A Phase II clinical trial and exploratory analysis.
Fang Z. et al, (2023), Nat Commun, 14
Outcomes and Characteristics of Non-Melanoma Skin Cancers in Patients with Myeloproliferative Neoplasms on Ruxolitinib.
Rampotas A. et al, (2023), Blood